Emergent BioSolutions (EBS) FCF Margin (2011 - 2026)

Emergent BioSolutions' FCF Margin history runs 16 years deep, the most recent figure standing at 23.19% for Q1 2026.

• In Q1 2026, FCF Margin fell 1747.0% year-over-year to 23.19%; the TTM figure through Mar 2026 stood at 21.5% (up 605.0% YoY), while the FY2025 annual figure was 22.75%, up 1731.0% from the prior year.
• FCF Margin was 23.19% for Q1 2026 at Emergent BioSolutions, down from 57.83% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 85.8% in Q2 2024 to a low of 116.74% in Q1 2023.
• Historically, FCF Margin has averaged 0.63% across 5 years, with a median of 5.72% in 2025.
• The sharpest annual moves came in 2023 and 2024: FCF Margin tumbled 10014 bps in 2023, then surged 11963 bps in 2024.
• A 5-year view of FCF Margin shows it stood at 53.18% in 2022, then tumbled by 107 bps to 3.72% in 2023, then slumped by 1006 bps to 41.19% in 2024, then surged by 240 bps to 57.83% in 2025, then plunged by 140 bps to 23.19% in 2026.
• The last three FCF Margin figures came in at 23.19% (Q1 2026), 57.83% (Q4 2025), and 4.33% (Q3 2025), per Business Quant data.